<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501487</url>
  </required_header>
  <id_info>
    <org_study_id>P0334</org_study_id>
    <nct_id>NCT01501487</nct_id>
  </id_info>
  <brief_title>MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I</brief_title>
  <acronym>MINT</acronym>
  <official_title>MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agendia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Morton Plant Mease Health Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Florida Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Plano Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Agendia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genomics assays that measure specific gene expression patterns in a patient's primary tumor
      have become important prognostic tools for breast cancer patients. This study is designed to
      test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and
      TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict
      responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer
      (LABC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with suspected primary breast cancer on mammography and clinical examination will be
      assessed for eligibility by having a needle core biopsy to confirm invasive carcinoma.

      A fresh unfixed tumor specimen, incisional or core biopsy will be sent to Agendia to
      determine the MammaPrint risk profile, the BluePrint molecular subtyping profile, the
      TargetPrint ER, PR and HER2 single gene readout, the 56-geneTheraPrint Research Gene Panel
      and the additional genes as measured on the whole genome (44k) array.

      Surgical Protocol:

        1. Determination of nodal status:

             -  For clinically node-negative patients: Axillary ultra sound, followed by Sentinel
                Lymph Node (SLN) biopsy

             -  For clinically node-positive patients: ultra sound-guided Fine Needle Aspirate
                (FNA), followed by core biopsy

        2. Neo-adjuvant chemotherapy

        3. Definitive surgery:

             -  For node-positive patients: lumpectomy, repeat SLN biopsy, Axillary Lymph Node
                Dissection (ALND)

             -  For node-negative patients: lumpectomy, repeat SLN biopsy (optional), no ALND

      Response will be measured by pathological Complete Response (pCR) and by centrally assessed
      Residual Cancer Burden (RCB).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the predictive power of chemosensitivity of MammaPrint as measured by pCR.</measure>
    <time_frame>6-12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the predictive power of chemosensitivity of the combination of MammaPrint and BluePrint as measured by pCR.</measure>
    <time_frame>6-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare TargetPrint single gene read out of ER, PR and HER2 with local and centralized IHC and/or CISH/FISH assessment of ER, PR and HER2.</measure>
    <time_frame>Baseline. First study visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify possible correlations between the TheraPrint Research Gene Panel outcomes and chemoresponsiveness.</measure>
    <time_frame>6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify and/or validate predictive gene expression profiles of clinical response/resistance to chemotherapy.</measure>
    <time_frame>6-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the three BluePrint molecular subtype categories with IHC-based subtype classification.</measure>
    <time_frame>Baseline. First study visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HER2 negative patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In order to provide some consistency in management and have a treatment policy in place only recommended therapy with several well accepted and presumed equivalent chemotherapy regimens will be used. The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients include:
TAC chemotherapy
TC chemotherapy
Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her2 positive patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients is TCH chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAC chemotherapy</intervention_name>
    <description>Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles</description>
    <arm_group_label>HER2 negative patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC chemotherapy</intervention_name>
    <description>Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles</description>
    <arm_group_label>HER2 negative patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy</intervention_name>
    <description>Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles</description>
    <arm_group_label>HER2 negative patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCH chemotherapy</intervention_name>
    <description>Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.</description>
    <arm_group_label>Her2 positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T + trastuzumab followed by CEF + trastuzumab</intervention_name>
    <description>Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.
Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr</description>
    <arm_group_label>Her2 positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose dense AC followed by T + trastuzumab</intervention_name>
    <description>Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).
Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.</description>
    <arm_group_label>Her2 positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose dense AC followed by T + trastuzumab + pertuzumab</intervention_name>
    <description>Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.</description>
    <arm_group_label>Her2 positive patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTH followed by dose dense AC of FEC</intervention_name>
    <description>Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,
Followed by 4 cycles of AC or FEC:
AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles
In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel.</description>
    <arm_group_label>Her2 positive patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histologically proven invasive breast cancer and no distant metastases and;

          -  Lymphnode negative and a clinical tumor classification of T2 (≥3.5cm)-T4 or with 1-3
             positive lymph nodes and a clinical tumor classification of T2-T4 DCIS or LCIS are
             allowed in addition to invasive cancer at T2 or T3 level.

          -  Age ≥ 18 years.

          -  At least one lesion that can be accurately measured in two dimensions utilizing
             mammogram, ultrasound, or MRI images to define specific size and validate complete
             pathologic response.

          -  Adequate bone marrow reserves (neutrophil count &gt;1.5 x109 /l and platelet count &gt;100
             x109/l), adequate renal function (serum creatinine ≤ 1.5 x upper limit of normal) and
             hepatic function (ALAT, ASAT ≤ 2.5 x upper limit of normal, alkaline phosphatase ≤ 2.5
             x upper limit of normal and total bilirubin ≤ 2.0 x upper limit of normal).

          -  Signed informed consent of the patient

        Exclusion Criteria:

          -  Any patient with confirmed metastatic disease. Patients with inflammatory breast
             cancer.

          -  Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails Quality Assurance
             or Quality Control criteria.

          -  Patients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for
             the treatment of breast cancer.

          -  Any serious uncontrolled intercurrent infections, or other serious uncontrolled
             concomitant disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles E Cox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama, Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Mease Health Care</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Breast Cancer Program</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen Ellis Memorial Hospital</name>
      <address>
        <city>Tarpon Springs</city>
        <state>Florida</state>
        <zip>34689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastchester Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma, Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health, Plano Cancer Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neo adjuvant therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

